Coronavirus information

Visitor restrictions, information for patients and more.

View coronavirus information

FOI 0584 Crohn’s Disease & Ulcerative Colitis Treatments 2019/20

Freedom of Information Request: 0584 2019/20

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018.  Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

Queen Elizabeth Hospital Birmingham:

  1. Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn’s Disease, for each of the following treatments:

 

Adalimumab [Amgevita] – 1

Adalimumab [Hulio] – 1

Adalimumab [Humira] – 1

Adalimumab [Hyrimoz] – 1

Adalimumab [Imraldi] – 1

Infliximab [Flixabi] – 0

Infliximab [Inflectra] – 0

Infliximab [Remicade] – 0

Infliximab [Remsima] – 0

Ustekinumab [Stelara] – 1

Vedolizumab [Entyvio] – 2

 

  1. Also, could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Ulcerative Colitis, for each of the following treatments:

 

Adalimumab [Amgevita] – 0

Adalimumab [Hulio] – 0

Adalimumab [Humira] – 0

Adalimumab [Hyrimoz] – 0

Adalimumab [Imraldi] – 0

Golimumab [Simponi] – 0

Infliximab [Flixabi] – 0

Infliximab [Inflectra] – 2

Infliximab [Remicade] – 0

Infliximab [Remsima] – 0

Tofacitinib [Xeljanz] – 0

Ustekinumab [Stelara] – 0

Vedolizumab [Entyvio] – 2

 

If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.

 

 

Heartlands, Good Hope and Solihull Hospitals:

  1. Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn’s Disease, for each of the following treatments:

 

Adalimumab [Amgevita]

Adalimumab [Hulio]

Adalimumab [Humira]

Adalimumab [Hyrimoz]

Adalimumab [Imraldi]

Infliximab [Flixabi]

Infliximab [Inflectra]

Infliximab [Remicade]

Infliximab [Remsima]

Ustekinumab [Stelara]

Vedolizumab [Entyvio]

 

We are unable to provide the data by disease/indication for Heartlands, Good Hope and Solihull Hospitals – please see total treatment numbers below

 

  1. Also, could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Ulcerative Colitis, for each of the following treatments:

 

Adalimumab [Amgevita]

Adalimumab [Hulio]

Adalimumab [Humira]

Adalimumab [Hyrimoz]

Adalimumab [Imraldi]

Golimumab [Simponi]

Infliximab [Flixabi]

Infliximab [Inflectra]

Infliximab [Remicade]

Infliximab [Remsima]

Tofacitinib [Xeljanz]

Ustekinumab [Stelara]

Vedolizumab [Entyvio]

 

We are unable to provide the data by disease/indication for Heartlands, Good Hope and Solihull Hospitals – please see total treatment numbers below

 

 

If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.

Total number of patients regardless of disease/indication for October – December 2019:

 

ADALIMUMAB                       654

GOLIMUMAB                         49

INFLIXIMAB (Inflectra)           141

INFLIXIMAB (Remicade)       1

TOFACITINIB                         20

USTEKINUMAB                     121

VEDOLIZUMAB                     62

Thinking of going to Accident and Emergency but not sure if you need to? Try our handy symptom checker.

Try ask A&E

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.